An Efficacy and Safety Study of Luspatercept (ACE-536) Versus Placebo in Adults Who Require Regular Red Blood Cell Transfusions Due to Beta (β) Thalassemia (BELIEVE)

• ClinicalTrials.gov Identifier: NCT02604433
• Recruitment Status: Completed
• First Posted: November 13, 2015
• Results First Posted: January 27, 2020
• Last Update Posted: April 18, 2023
• Sponsor: Celgene
• Collaborator: Acceleron Pharma, Inc., a wholly-owned subsidiary of Merck & Co., Inc., Rahway, NJ USA
• Information provided by (Responsible Party): Celgene

Study Description

Brief Summary:

This is a Phase 3, double-blind, randomized, placebo-controlled, multicenter study to determine the efficacy and safety of luspatercept (ACE-536) plus Best supportive care (BSC) versus placebo plus BSC in adults who require regular red blood cell transfusion due to (β)-thalassemia.

The study is divided into the following periods:

• Historical Period,
• Screening/Run-in Period,
• Double-blind Treatment Period (48 weeks),
• Double-blind Long-term Treatment Period, (at the investigator's discretion an additional 48 weeks),
• Open-Label Phase post unblinding and upon Data Monitoring Committee positive recommendation
• Post-treatment Follow-up Period

Condition or disease	Intervention/treatment	Phase
Erythrocyte Transfusion; Beta-Thalassemia	Drug: Luspatercept; Other: Placebo	Phase 3

Study Design

• Study Type: Interventional (Clinical Trial)
• Actual Enrollment: 336 participants
• Allocation: Randomized
• Intervention Model: Parallel Assignment
• Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
• Primary Purpose: Treatment
• Official Title: A Phase 3, Double-Blind, Placebo Controlled Multicenter Study to Determine the Efficacy and Safety of Luspatercept (ACE-536) in Adults With Transfusion Dependent Beta (B)-Thalassemia
• Actual Study Start Date: May 2, 2016
• Actual Primary Completion Date: January 5, 2021
• Actual Study Completion Date: January 5, 2021

Arms and Interventions

Arm	Intervention/treatment
Experimental: Luspatercept (ACE-536) plus Best Supportive Care (BSC); Luspatercept, subcutaneous(ly) (SC) once every 21 days	Drug: Luspatercept; Subjects will start with luspatercept at 1 mg/kg dose level.; Other Name: ACE-536
Placebo Comparator: Placebo plus Best Supportive Care (BSC); normal saline solution subcutaneous(ly) (SC) once every 21 days	Other: Placebo; Placebo, Subcutaneous, every 21 days.

Outcome Measures

Primary Outcome Measures :

1. Percentage of Participants Who Achieved Erythroid Response - Week 13 to Week 24 [ Time Frame: Baseline: Day -83 to Day 1; Treatment: Weeks 13 to Week 24 ]
   Erythroid Response was defined as red blood cell (RBC) transfusion burden reduction from baseline ≥ 33% with a reduction of at least 2 units during Week 13 - 24 compared to the 12-week interval on or prior to Dose 1 Day 1.

Secondary Outcome Measures :

1. Percentage Of Participants Who Achieved ≥ 33% Reduction From Baseline in Transfusion Burden - Week 37 to Week 48 [ Time Frame: Baseline: Day -83 to Day 1; Treatment: Weeks 37 to Week 48 ]
   Percentage of participants who achieved a red blood cell (RBC) transfusion burden reduction from baseline ≥ 33% with a reduction of at least 2 units during Weeks 37 - 48 compared to the 12-week interval on or prior to Dose 1 Day 1.
2. Percentage Of Participants Who Achieve ≥ 50% Reduction From Baseline in Transfusion Burden - Week 13 to Week 24 [ Time Frame: Baseline: Day -83 to Day 1; Treatment: Weeks 13 to Week 24 ]
   Percentage of participants who achieved a red blood cell (RBC) transfusion burden reduction from baseline ≥ 50% with a reduction of at least 2 units during Weeks 13 - 24 compared to the 12-week interval on or prior to Dose 1 Day 1.
3. Percentage Of Participants Who Achieve ≥ 50% Reduction From Baseline in Transfusion Burden - Week 37 to Week 48 [ Time Frame: Baseline: Day -83 to Day 1; Treatment: Week 37 to Week 48 ]
   Percentage of participants who achieved a red blood cell (RBC) transfusion burden reduction from baseline ≥ 50% with a reduction of at least 2 units during Week 37 to Week 48 compared to the 12-week interval on or prior to Dose 1 Day 1.
4. Mean Change From Baseline in Transfusion Burden - Week 13 to Week 24 [ Time Frame: Baseline: Day -83 to Day 1; Treatment: Weeks 13 to Week 24 ]
   Baseline was defined as the total number of Red Blood Cells (RBC) units transfused during the 12-week interval on or prior to Dose 1 Day 1. This is compared to the total number of RBC units transfused during the 12-week interval from treatment weeks 13-24.
5. Mean Change From Baseline In Liver Iron Concentration (LIC) At Week 48 [ Time Frame: Baseline: Week -12 to Day -1; Treatment: Week 48 ]
   Baseline was defined as the last value on or before the first dose of study drug was administered; if multiple values were present for the same date, the average of these values was used. If a participant had 1 postbaseline assessment, it was used as the Week 48 value. If a participant had multiple postbaseline assessments, the last one was used as the Week 48 value. The value of LIC was collected by magnetic resonance imaging. Participants with a LIC value > 43 mg/g were not included in the analysis.
6. Mean Change From Baseline In Mean Daily Dose Of Iron Chelation Therapies (ICT) At Week 48 [ Time Frame: Baseline: Day -83 to Day 1; Treatment: Week 37 to Week 48 ]
   Three different types of Iron Chelation Therapy (ICT) were analyzed: 1. Deferasirox 2. Deferiprone 3. Deferoxamine Mesilate/Deferoxamine The baseline mean daily dose was calculated using the ICT dosage during the 12 weeks prior to first study drug administration and the postbaseline mean daily dose was calculated during the last 12 weeks of the 48-week double-blind Treatment Period or the last 12 weeks of the study treatment for early discontinued participants.
7. Mean Change From Baseline In Mean Serum Ferritin At Week 48 [ Time Frame: Baseline: Day -83 to Day 1; Treatment: Week 37 to Week 48 ]
   For each participant, the baseline mean serum ferritin level was calculated during the 12 weeks prior to first study drug administration. The postbaseline mean serum ferritin level was calculated during the last 12 weeks of the 48-week double-blind Treatment Period or last 12 weeks of study treatment, if discontinued early. The change was calculated as the difference of post baseline mean serum ferritin level and baseline mean serum ferritin level.
8. Mean Change From Baseline In Total Hip And Lumbar Spine Bone Mineral Density (BMD) At Week 48 [ Time Frame: Baseline: Day 1; Treatment: Week 48 ]
   For BMD, the lumbar spine and total hip were measured at baseline and 48 weeks by dual energy x-ray absorptiometry (DXA). Baseline was defined as the last value on or before the first dose of study drug is administered; if multiple values are present for the same date, the average of these values was used. If during the 48 week double-blinded treatment period, a participant has only one assessment, it is counted as 'Week 48' visit; if a participant has multiple assessments, the last one is used as 'Week 48' visit. The analysis was done on the population that had at least 2 measurements.
9. Mean Change From Baseline In Myocardial Iron At Week 48 [ Time Frame: Baseline: Day 1; Treatment: Week 48 ]
   Myocardial Iron levels were measured by Magnetic Resonance Imaging (MRI), using MRI parameter T2* (Unit: ms). T2* values correlates with heart failure (HF) risk (e.g. T2*<6ms: high HF risk).
10. Mean Change From Baseline in the Transfusion-dependent Quality of Life (TranQol) Questionnaire At Week 24 [ Time Frame: Baseline: 4 weeks prior to Day 1; Treatment: Week 24 ]
    The TranQol is a self-administered quality of life tool developed for beta-thalassemia patients. The adult self-report version used in this study, includes 36 questions assessed on a 5-point response, that are grouped into 5 domains (Physical Health, Emotional Health, Sexual Health, Family Functioning, School/Career Functioning). Scores are calculated according to specific scoring algorithms developed by the authors. Both individual domains score and the total score range from 0 (worst) to 100 (best). Total Score and Physical Health domain score are reported. Positive change from baseline values indicate improvement.
11. Mean Change From Baseline in the 36-item Short Form Health Survey (SF-36) Questionnaire At Weeks 24 [ Time Frame: Baseline: 4 weeks prior to Day 1; Treatment: Weeks 24 ]
    The SF-36 (version 2) is a generic, self-administered instrument consisting of 8 multi-item scales that assess 8 health domains. The raw score for each health domain is transformed into a 0 (worst) to 100 (best) domain score. The 0-100 scale score for each health domain is further converted to normbased scores using a T-score transformation, with a mean of 50 and a standard deviation (SD) of 10. Higher norm-based T-scores indicate better heath/QoL. The domains/summaries reported are: 1. Physical Functioning (Range of possible T-scores is 19.26 - 57.54) 2. General Health (Range of possible T-scores is 18.95 - 66.50) 3. Physical Component summary (PCS) (Range of possible T-scores is 5.02 - 79.78). Positive change from baseline values indicate improvement.
12. Number of Participants Who Utilized Healthcare Resources During Study [ Time Frame: From informed consent signing (up to 12 weeks before start of treatment) to end of treatment (up to approximately 227 weeks) ]
    Number of participants who had any of the following types of Healthcare Resource Utilization (HRU): - a doctor office visit (non-study scheduled) - an emergency department visit - a hospitalization
13. Number of Days Spent in Higher Care Hospital Units [ Time Frame: From informed consent signing (up to 12 weeks before start of treatment) to end of treatment (up to approximately 227 weeks) ]
    Types of hospitals units considered to be 'higher care' are: - Intensive Care Unit - Coronary Care Unit
14. Percentage Of Participants Who Were Transfusion Independent For ≥ 8 Weeks During Treatment [ Time Frame: From first dose through 3 weeks post last dose (up to approximately 218 weeks) ]
    Transfusion independence was defined as the absence of any transfusion during any consecutive "rolling" 8-week time interval within the treatment period, i.e, Days 1 to 56, Days 2 to 57 and so on.
15. Duration of Reduction in Transfusion Burden [ Time Frame: From first dose to end of study treatment (up to approximately 215 weeks) ]
    Responders were defined as subjects who achieved ≥ 33% reduction or ≥ 50% reduction in Red Blood Cells Transfusion (RBC-T) burden from baseline with a reduction of at least 2 RBC units during any rolling 12-week interval. The duration of reduction is calculated as Last Day of Response - First day of response +1
16. Longest Duration of Transfusion Independence [ Time Frame: From first dose through 3 weeks post last dose (up to approximately 218 weeks) ]
    Transfusion independence was defined as the absence of any transfusion during any consecutive "rolling" 8-week time interval within the treatment period, ie, Days 1 to 56, Days 2 to 57 and so on. Longest duration of transfusion independence was estimated based on Kaplan-Meier model.
17. Time to Erythroid Response [ Time Frame: From first dose to 48 weeks following first dose ]
    Time to erythroid response was defined as the time from first dose of the study drug to first erythroid response. This is reported for participants with a ≥ 33% reduction from baseline in RBC transfusion burden (with a reduction of at least 2 units) for any 12-week interval., as well as participants with a ≥ 50% reduction from baseline in RBC transfusion burden (with a reduction of at least 2 units) for any 12-week interval.
18. Post-Baseline Transfusion Event Frequency [ Time Frame: From first dose through 3 weeks post last dose (up to approximately 218 weeks) ]
    The number of transfusion events after start of study treatment were evaluated. For the definition of transfusion events, if multiple transfusions happen on the same date, they are counted as one event; if multiple transfusions happen on two consecutive dates, they are counted as one event; if multiple transfusions happen on three consecutive dates, they are counted as two events. Results are presented in 24-week intervals, up to 96 weeks after start of study treatment
19. Pharmacokinetic (PK) Parameters: Bayesian Estimate of Apparent Clearance (CL/F) [ Time Frame: Blood serum samples taken pre-dose and on Days 1, 22, 64, 85, 106, 127, 169, 211, 253, 295, 337 ]
20. Pharmacokinetic (PK) Parameters: Bayesian Estimate of Apparent Volume of Distribution of the Central Compartment (V1/F) [ Time Frame: Blood serum samples taken pre-dose and on Days 1, 22, 64, 85, 106, 127, 169, 211, 253, 295, 337 ]
21. Pharmacokinetic (PK) Parameters: Bayesian Estimate of Elimination Half-life (t1/2) [ Time Frame: Blood serum samples taken pre-dose and on Days 1, 22, 64, 85, 106, 127, 169, 211, 253, 295, 337 ]
22. Pharmacokinetic (PK) Parameters: Bayesian Estimate of Time to Reach Maximum Concentration (Tmax) [ Time Frame: Blood serum samples taken pre-dose and on Days 1, 22, 64, 85, 106, 127, 169, 211, 253, 295, 337 ]
23. Pharmacokinetic (PK) Parameters: Bayesian Estimate of Maximum Concentration for the Starting Dose (Cmax) [ Time Frame: Blood serum samples taken pre-dose and on Days 1, 22, 64, 85, 106, 127, 169, 211, 253, 295, 337 ]
24. Pharmacokinetic (PK) Parameters: Bayesian Estimate of Maximum Concentration at Steady State for the Starting Dose (Cmax,ss) [ Time Frame: Blood serum samples taken pre-dose and on Days 1, 22, 64, 85, 106, 127, 169, 211, 253, 295, 337 ]
25. Pharmacokinetic (PK) Parameters: Bayesian Estimate of Area Under the Concentration-Time Curve at Steady State for the Starting Dose (AUCss) [ Time Frame: Blood serum samples taken pre-dose and on Days 1, 22, 64, 85, 106, 127, 169, 211, 253, 295, 337 ]
26. Participants With Treatment-Emergent Adverse Events (TEAE) [ Time Frame: From first dose to 90 days following last dose (up to approximately 52 months) ]
    An AE is any noxious, unintended, or untoward medical occurrence that may appear or worsen during the course of a study. A serious AE is any AE occurring at any dose that - Results in death - Is life-threatening - Requires or prolongs existing inpatient hospitalization - Results in persistent or significant disability/incapacity - Is a congenital anomaly/birth defect - Constitutes an important medical event. The Investigator assessed the relationship of each AE to study drug and graded the severity according to the National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE, Version 4.03): - Grade 1 = Mild - Grade 2 = Moderate (some limitation in activity; no/minimal medical intervention) - Grade 3 = Severe (limitation in activity; medical intervention required) - Grade 4 = Life-threatening - Grade 5 = Death
27. Participants With Pre-Existing and/or Treatment-Emergent Antidrug Antibodies (ADA) [ Time Frame: Timeframe: pre-dose, Day 1, Days 22, 64, 106, 148, 232, 316 ]
    Number of participants with positive ADA prior to taking study drug and/or during study. A participant was counted as "treatment-emergent" if there was a positive post-baseline sample while the baseline sample was ADA negative, or there was a positive post-baseline sample with a titer ≥ 4-fold of the baseline titer while the baseline sample was ADA positive. A participant was counted as "preexisting" if the baseline sample was ADA positive and the participant was not qualified for "treatment-emergent."

Eligibility Criteria

• Ages Eligible for Study: 18 Years and older (Adult, Older Adult)
• Sexes Eligible for Study: All
• Accepts Healthy Volunteers: No

Criteria

Inclusion Criteria:

Subjects must satisfy the following criteria to be enrolled in the study:

1. Male or female, ≥18 years of age at the time of signing the informed consent document (ICF).
2. Subject must understand and voluntarily sign an Inform Consent Form prior to any study-related assessments/procedures being conducted.
3. Subject is willing and able to adhere to the study visit schedule and other protocol requirements.
4. Documented diagnosis of β-thalassemia or Hemoglobin E/β-thalassemia. (β-thalassemia with mutation and/or multiplication of alpha globin is allowed).

5. Regularly transfused, defined as: 6-20 Red Blood Cell (RBC) units* in the 24 weeks prior to randomization and no transfusion-free period for ≥ 35 days during that period.

   * Sites who prescribe transfusions and have the transfusion records only in volumes should use for conversion of volume to units the below criteria, in order to obtain number of units within the last 24 weeks to assess the eligibility: 1 unit in this protocol refers to a quantity of packed RBCs approximately 200-350 mL. (i) sites who use transfusion bags within this range, or ≥ 350 mL, the conversion in units should be done by dividing the volume transfused to the patient by 350 mL, (ii) sites who use transfusion bags < 200 mL, the conversion in units should be done by dividing the volume transfused to the patient by 200 mL.

6. Performance status: Eastern Cooperative Oncology Group (ECOG) score of 0 or 1.

7. A female of childbearing potential (FCBP) for this study is defined as a female who: 1) has achieved menarche at some point, 2) has not undergone a hysterectomy or bilateral oophorectomy or 3) has not been naturally postmenopausal (amenorrhea following cancer therapy does not rule out childbearing potential) for at least 24 consecutive months (ie, has had menses at any time in the preceding 24 consecutive months). FCBP participating in the study must:

   1. Have two negative pregnancy tests as verified by the Investigator prior to starting study therapy. She must agree to ongoing pregnancy testing during the course of the study, and after end of study treatment. This applies even if the subject practices true abstinence ** from heterosexual contact.

   2. Either commit to true abstinence** from heterosexual contact (which must be reviewed on a monthly basis and source documented) If a FCBP engages in sexual activity that may result in a pregnancy, she must agree to use, and be able to comply with, effective*** contraception without interruption, 28 days prior to starting investigational product, during the study therapy (including dose interruptions), and for 12 weeks (approximately five times the mean terminal half-life of luspatercept based on multiple-dose Pharmacokinetic PK) data) after discontinuation of study therapy.

      • True abstinence is acceptable when this is in line with the preferred and usual lifestyle of the subject. [Periodic abstinence (eg, calendar, ovulation, symptothermal, post-ovulation methods) and withdrawal are not acceptable methods of contraception.] *** Agreement to use highly effective methods of contraception that alone or in combination result in a failure rate of a Pearl index of less than 1% per year when used consistently and correctly throughout the course of the study.

   Such methods include: Combined (estrogen and progesterone/progestin containing) hormonal contraception: Oral; Intravaginal; Transdermal; Progestogen/progestin only hormonal contraception associated with inhibition of ovulation: Oral; Injectable hormonal contraception; Implantable hormonal contraception; Placement of an intrauterine device (IUD); Placement of an intrauterine hormone-releasing system (IUS); Bilateral tubal occlusion; Vasectomized partner; Sexual Abstinence.

8. Male subjects must:

   • Practice true abstinence or agree to use a condom during sexual contact with a pregnant female or a female of childbearing potential while participating in the study, during dose interruptions and for at least 12 weeks (approximately five times the mean terminal half-life of luspatercept based on multiple-dose PK data) following investigational product discontinuation, even if he has undergone a successful vasectomy.

Exclusion Criteria:

The presence of any of the following will exclude a subject from enrollment:

1. Any significant medical condition, laboratory abnormality, or psychiatric illness that would prevent the subject from participating in the study.
2. Any condition including the presence of laboratory abnormalities, which places the subject at unacceptable risk if he/she were to participate in the study.
3. Any condition that confounds the ability to interpret data from the study.
4. A diagnosis of Hemoglobin S/β-thalassemia or alpha (α)-thalassemia (eg, Hemoglobin H);

5. Evidence of active hepatitis C (HCV) infection as demonstrated by a positive HCV-RNA test of sufficient sensitivity, or active infectious hepatitis B as demonstrated by the presence of HBsAg and/or HBVDNA-positive,, or known positive human immunodeficiency virus (HIV).

   Note: Subjects receiving antiviral therapies should have 2 negative HCVRNA tests 3 months apart.(ie, one test at the end of the antiviral therapy and a second test 3 months following the first test).

6. Deep Vein Thrombosis (DVT) or stroke requiring medical intervention ≤ 24 weeks prior to randomization.
7. Use of chronic anticoagulant therapy is excluded, unless the treatment stopped at least 28 days prior to randomization. Anticoagulant therapies used for prophylaxis for surgery or high risk procedures as well as low Molecular Weight (LMW) heparin for superficial venous thrombosis and chronic aspirin are allowed.
8. Platelet count > 1000 x 109/L
9. Poorly controlled diabetes mellitus within 24 weeks prior to randomization as defined by short term (eg, hyperosmolar or ketoacidotic crisis) and/or history of diabetic cardiovascular complications (eg, stroke or myocardial infarction).
10. Treatment with another investigational drug or device ≤ 28 days prior to randomization.
11. Prior exposure to sotatercept (ACE-011) or luspatercept (ACE-536).
12. Use of an erythropoiesis-stimulating agent (ESA) ≤ 24 weeks prior to randomization.
13. Iron chelation therapy, if initiated ≤ 24 weeks prior to randomization (allowed if initiated > 24 weeks before or during treatment).
14. Hydroxyurea treatment ≤ 24 weeks prior to randomization.
15. Pregnant or lactating females.
16. Uncontrolled hypertension. Controlled hypertension for this protocol is considered ≤ Grade 1 according to NCI Common Terminology Criteria for Adverse Events (CTCAE) version 4.0 (current active minor version).

17. Major organ damage, including:

    1. Liver disease with alanine aminotransferase (ALT) > 3 x the upper limit of normal (ULN) or history of evidence of cirrhosis;
    2. Heart disease, heart failure as classified by the New York Heart Association (NYHA) classification 3 or higher, or significant arrhythmia requiring treatment, or recent myocardial infarction within 6 months of randomization.
    3. Lung disease, including pulmonary fibrosis or pulmonary hypertension which are clinically significant ie, ≥ Grade 3 NCI CTCAE version 4.0 (current active minor version).
    4. Creatinine clearance < 60 mL/min (per Cockroft-Gault formula).
18. Proteinuria ≥ Grade 3 according to NCI CTCAE version 4.0 (current active minor version).
19. Chronic systemic glucocorticoids ≤ 12 weeks prior to randomization (physiologic replacement therapy for adrenal insufficiency is allowed). Single day glucocorticoid treatment (eg, for prevention or treatment of transfusion reactions, is allowed).
20. Major surgery ≤ 12 weeks prior to randomization (subjects must have completely recovered from any previous surgery prior to randomization).
21. History of severe allergic or anaphylactic reactions or hypersensitivity to recombinant proteins or excipients in the investigational product (see Investigator Brochure).
22. Cytotoxic agents, immunosuppressants ≤ 28 days prior to randomization (ie, antithymocite globulin (ATG) or cyclosporine)

23. History of malignancy with the exception of:

    1. Curatively resected nonmelanoma skin cancer.
    2. Curatively treated cervical carcinoma in situ.
    3. Other solid tumor with no known active disease in the opinion of the investigator.

Contacts and Locations

Locations

United States, California

Children's Hospital of Los Angeles

Los Angeles, California, United States, 90027

Children's Hospital and Research Center at Oakland

Oakland, California, United States, 94609

United States, Illinois

Ann and Robert H Lurie Childrens Hospital of Chicago

Chicago, Illinois, United States, 60611

United States, Massachusetts

Boston Children's Hospital

Boston, Massachusetts, United States, 02115

United States, New York

Weill Cornell Medical College

New York, New York, United States, 10065

United States, Pennsylvania

Hospital of the University of Pennsylvania

Philadelphia, Pennsylvania, United States, 19104

Australia, New South Wales

Prince of Wales Hospital

Randwick, New South Wales, Australia, 2031

Australia, Queensland

Mater Hospital Brisbane

South Brisbane, Queensland, Australia, 4101

Australia, South Australia

Royal Adelaide Hospital Institute of Medical and Veterinary Science

Adelaide, South Australia, Australia, 5000

Australia, Victoria

Monash Medical Centre

Clayton, Victoria, Australia, 3168

Australia, Western Australia

Sir Charles Gairdner Hospital

Nedlands, Western Australia, Australia, 6009

Australia

Royal Prince Alfred Hospital

Camperdown, Australia, 2050

Bulgaria

University Mulitiprofile Hospital for Active Treatment Sveti Georgi EAD

Plovdiv, Bulgaria, 4002

Specialized Hospital for Active Treatment of Haematological Diseases - Sofia

Sofia, Bulgaria, 1756

Multiprofile Hospital for Active Treatment Sveta Marina EAD

Varna, Bulgaria, 9010

Canada, Ontario

University Health Network

Toronto, Ontario, Canada, M5G 2C4

France

Hopital Henri Mondor

Creteil, France, 94010

GH de Institut Catholique St. VincentHématologie

Lille, France, 59000

Hopitaux de La Timone

Marseille Cedex 9, France, 13385

Hospital of Necker

Paris, France, 75015

Greece

Laiko General Hospital of Athens

Ampelokipi - Athens, Greece, 115 26

Local Institution - 405

Ampelokipi - Athens, Greece, 115 26

General Children's Hospital "Agia Sophia"

Athens, Greece, 115 27

General Hospital Georgios Gennimatas of Athens

Athens, Greece, 11527

University General Hospital of Patras

Rio Patras, Greece, 26500

Hippokration Hospital

Thessaloniki, Greece, 54642

Local Institution - 404

Thessaloniki, Greece, 54642

Israel

Soroka University Medical Centre

Beer Sheva, Israel, 84101

Rambam Health Corporation

Haifa, Israel, 3109601

HaEmek Medical Center

Haïfa (Afula), Israel, 18101

Shaare Zedek Medical Center

Jerusalem, Israel, 91031

Hadassah Medical Center

Jerusalem, Israel, 91120

Galilee Medical Center

Nahariya, Israel, 22100

Rabin Medical Center

Petah Tikva, Israel, 49100

Italy

Presidio Ospedaliero Antonio Perrino

Brindisi, Italy, 72100

Universita degli Studi di Cagliari - ASL8

Cagliari, Italy, 09121

Azienda Ospedaliero-Universitaria di Ferrara - Arcispedale Sant'Anna

Ferrara, Italy, 44124

Ente Ospedaliero Ospedali Galliera - Centro della Microcitemia e delle Anemie Congenite

Genoa, Italy, 16128

Fondazione Ca Granda IRCCS Ospedale Maggiore

Milan, Italy, 20122

Seconda Universita Degli Studi Di Napoli

Naples, Italy, 80131

AORN A Cardarelli

Napoli, Italy, 80131

Azienda Ospedaliero Universitaria S. Luigi Gonzaga

Orbassano, Italy, 10043

Azienda Ospedaliera Ospedali Riuniti Villa Sofia-Cervello

Palermo, Italy, 90146

Azienda Ospedaliera Universitaria Integrata Di Verona

Verona, Italy, 37134

Lebanon

Chronic Care Center

Beirut, Lebanon

Malaysia

Hospital Sultanah Aminah

Johor Bahru, Johor, Malaysia, 80100

Hospital Sultanah Bahiyah

Alor Setar, Kedah, Malaysia, 05460

Hospital Raja Permaisuri Bainun

Ipoh, Perak, Malaysia, 30990

Queen Elizabeth Hospital

Kota Kinabalu, Sabah, Malaysia, 88586

Hospital Umum Sarawak

Kuching, Sarawak, Malaysia, 93586

University Malaya Medical Centre

Kuala Lumpur, Wilayah Persekutuan Kuala Lumpur, Malaysia, 59100

Hospital Pulau Pinang c/o Penang Medical College

Georgetown, Malaysia, 10990

Taiwan

Changhua Christian Hospital

Changhua City, Taiwan, 500

Kaohsiung Medical University Hospital

Kaohsiung, Taiwan, 807

China Medical University Hospital

Taichung, Taiwan, 40447

National Taiwan University Hospital

Taipei, Zhongzheng Dist., Taiwan, 10002

Thailand

Chulalongkorn University Faculty of Medicine - King Chulalongkorn Memorial Hospital

Bangkok, Thailand, 10330

Siriraj Hospital Mahidol University

Bangkok, Thailand, 10700

Chiang Mai University - Maharaj Nakorn Chiang Mai Hospital

Chiang Mai, Thailand, 50200

Tunisia

University Hospital Farhat Hached

Sousse, Tunisia, 4031

Bone Marrow Transplant Center

Tunis, Tunisia, 1006

Aziza Othmana Hospital

Tunis, Tunisia, 1008

Military Hospital of Tunis

Tunis, Tunisia, 1089

Turkey

Acibadem Adana Hospital

Adana, Turkey, 01130

Cukurova University Medical Faculty Balcali Hospital

Adana, Turkey, 01330

Local Institution - 524

Adana, Turkey, 01330

Hacettepe Universitesi

Ankara, Turkey, 01660

Antalya Egitim Arastirma

Antalya, Turkey, 07100

Istanbul Universitesi Istanbul Tip Fakultesi Hastanesi

Istanbul, Turkey, 34093

Ege Universitesi Tip Fakultesi Hastanesi

Izmir, Turkey, 35100

Mersin University Medical Faculty

Mersin, Turkey, 33343

United Kingdom

St James University Hospital

Leeds, United Kingdom, LS9 7TF

University College Hospital Trust

London Bloomsbury, United Kingdom, WC1E 6AU

Barts Health NHS Trust - The Royal London Hospital

London, United Kingdom, E1 1BB

Whittington Hospital

London, United Kingdom, N19 5NF

Manchester Royal Infirmary

Manchester, United Kingdom, M13 9WL

Sponsors and Collaborators

Celgene

Acceleron Pharma, Inc., a wholly-owned subsidiary of Merck & Co., Inc., Rahway, NJ USA

Investigators

• Study Director: Bristol-Myers Squibb; Bristol-Myers Squibb

  Study Documents (Full-Text)

Documents provided by Celgene:

Study Protocol  [PDF] December 11, 2018

Statistical Analysis Plan  [PDF] March 11, 2021

More Information

Additional Information:

BMS Clinical Trial Information 

BMS Clinical Trial Patient Recruiting 

FDA Safety Alerts and Recalls 

Publications of Results:

Porter J. Beyond transfusion therapy: new therapies in thalassemia including drugs, alternate donor transplant, and gene therapy. Hematology Am Soc Hematol Educ Program. 2018 Nov 30;2018(1):361-370. doi: 10.1182/asheducation-2018.1.361.

Piga A, Perrotta S, Gamberini MR, Voskaridou E, Melpignano A, Filosa A, Caruso V, Pietrangelo A, Longo F, Tartaglione I, Borgna-Pignatti C, Zhang X, Laadem A, Sherman ML, Attie KM. Luspatercept improves hemoglobin levels and blood transfusion requirements in a study of patients with beta-thalassemia. Blood. 2019 Mar 21;133(12):1279-1289. doi: 10.1182/blood-2018-10-879247. Epub 2019 Jan 7.

Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):

Cappellini MD, Taher AT. The use of luspatercept for thalassemia in adults. Blood Adv. 2021 Jan 12;5(1):326-333. doi: 10.1182/bloodadvances.2020002725.

Cappellini MD, Viprakasit V, Taher AT, Georgiev P, Kuo KHM, Coates T, Voskaridou E, Liew HK, Pazgal-Kobrowski I, Forni GL, Perrotta S, Khelif A, Lal A, Kattamis A, Vlachaki E, Origa R, Aydinok Y, Bejaoui M, Ho PJ, Chew LP, Bee PC, Lim SM, Lu MY, Tantiworawit A, Ganeva P, Gercheva L, Shah F, Neufeld EJ, Thompson A, Laadem A, Shetty JK, Zou J, Zhang J, Miteva D, Zinger T, Linde PG, Sherman ML, Hermine O, Porter J, Piga A; BELIEVE Investigators. A Phase 3 Trial of Luspatercept in Patients with Transfusion-Dependent beta-Thalassemia. N Engl J Med. 2020 Mar 26;382(13):1219-1231. doi: 10.1056/NEJMoa1910182.

• Responsible Party: Celgene
• ClinicalTrials.gov Identifier: NCT02604433
• Other Study ID Numbers: ACE-536-B-THAL-001
• First Posted: November 13, 2015
• Results First Posted: January 27, 2020
• Last Update Posted: April 18, 2023
• Last Verified: March 2023

Keywords provided by Celgene:

ACE-536; Safety; Efficacy; Placebo; Red Blood Cell Transfusions; Beta -Thalassemia

Additional relevant MeSH terms:

Thalassemia; beta-Thalassemia; Anemia, Hemolytic, Congenital; Anemia, Hemolytic; Anemia; Hematologic Diseases; Hemoglobinopathies; Genetic Diseases, Inborn; Luspatercept; Hematinics